Adalimumab for maintenance therapy for one year in Crohn's disease: results of a Latin American single-center observational study.

Context: Adalimumab is a fully-human antibody that inhibits TNF alpha, with a significant efficacy for long-term maintenance of remission. Studies with this agent in Latin American Crohn's disease patients are scarce.

Objectives: The objective of this study was to outline clinical remission rates after 12 months of adalimumab therapy for Crohn's disease patients.